Literature Search

ACR Appropriateness Criteria®

Pretreatment Detection, Surveillance, and Staging of Prostate Cancer

Literature Search Performed on: 01/29/2021
Beginning Date: January 2000
End Date: December 2020
Database: Ovid MEDLINE(R) ALL <1946 to January 28, 2021>

Search Strategy

1 (prostate cancer and PSA Screening).af. (1092)
2 exp mortality/ or mortality.af. or mortalities.af. or mortality.sh. (1331242)
3 1 and 2 (406)
4 limit 3 to randomized controlled trial (31)
5 ferumoxtran-10.nm, rn, rx, ps, px. or ferumoxtran-10.af. or uspio.af. or uspios.af. (1158)
6 prostat.af. or exp prostate/ or prostate.af. or prostates.af. or prostatic.af. or exp prostatism/ or prostatism.af. or exp prostatitis/ or prostatitis.af. (256283)
7 5 and 6 (54)
8 cholin.af. or exp choline/ or choline.af. or cholines.af. or choline&amp;#39;s.af. (88824)
9 (exp risk/ or risk.af.) and (intermediate or intermediated or intermediary or intermediates or high).af. (800591)
10 exp risk/ or risk.af. (2762844)
11 (stage or staged or stages or staging or stagings).af. (1265856)
12 prostat.af. or exp prostate/ or prostate.af. or prostates.af. or prostatic.af. or exp prostatism/ or prostatism.af. or exp prostatitis/ or prostatitis.af. (256283)
13 (PET or positron emission).af. (143329)
14 metastas*.af. (478453)
15 8 and 9 and 10 and 11 and 12 and 13 and 14 (40)
16 ((fluciclovine or facbc) and (PET or positron emission)).af. (274)
17 (intermediate or intermediated or intermediary or intermediates or high).af. (4526771)
18 (exp risk/ or risk.af.) and (stage or staged or stages or staging or stagings).af. (197436)
19 metastas*.af. (478453)
20 (Prostat or prostate or prostates or prostatic or prostatism or prostatitis).af. or exp prostate/ or exp prostatism/ or exp prostatitis/ (256283)
21 16 and 17 and 18 and 19 and 20 (8)
22 4 or 7 or 15 or 21 (129)
23 limit 22 to yr="2000 -Current" (125)

Literature Search Performed on: 10/19/2020
Beginning Date: January 2016
End Date: September 2020
Database: Ovid MEDLINE(R) ALL <1946 to October 16, 2020>

Search Strategy

1 exp diagnostic imaging/ and *Prostatic Neoplasms/di, dg, pa and (Neoplasm grading/ or Neoplasm Staging/ or Prostate-Specific Antigen/ or prostate/ or Neoplasm Metastasis/) (5979)
2 Prospective Studies/ or Retrospective Studies/ or Comparative Study/ or Risk Assessment/ or Systematic Review/ (3318472)
3 1 and 2 (2550)
4 exp diagnostic imaging/ and *Prostatic Neoplasms/ (15735)
5 limit 4 to (meta analysis or randomized controlled trial or practice guideline) (464)
6 (Biomarkers and prostate cancer and psa and (Decipher or Oncotype or Prolaris or ProMark)).tw. (8)
7 *American Cancer Society/ and *SEER Program/ and Prostate.tw. (1)
8 PET MRI.kw. and prostate.ti. (41)
9 3 or 6 or 7 or 8 (2592)
References from the literature search that were not retained had a poor study design, were not relevant to the topic, or had unclear or biased results.

### Summary

<table>
<thead>
<tr>
<th>Source</th>
<th>#Unique Refs</th>
<th>#Retained Refs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Old bibliography</td>
<td>92</td>
<td>34</td>
</tr>
<tr>
<td>Literature Search(es)</td>
<td>1110</td>
<td>89</td>
</tr>
<tr>
<td>Author Added</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>Supporting Docs</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Total</td>
<td></td>
<td>124</td>
</tr>
</tbody>
</table>

References from the literature search that were not retained had a poor study design, were not relevant to the topic, or had unclear or biased results.